New pill targets genetic weakness in Hard-to-Treat blood cancers
NCT ID NCT04603001
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests an experimental oral drug called LY3410738 in people with advanced blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) that have specific IDH1 or IDH2 gene mutations. The drug is designed to block the mutated IDH proteins that help cancer grow. The trial aims to find the safest dose and measure how well the drug works, both alone and in combination with other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3410738
What this could lead to
If successful, this could provide a new targeted treatment option for people with certain blood cancers that have IDH1 or IDH2 mutations.
What could go wrong
This is an early phase 1 trial, so the drug may not work as hoped or could have unexpected side effects. The results are preliminary and may not lead to a widely available treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Caris Chromoseq vs Standard Testing for Blood Ca NCT07680868
- Venetoclax TDM Study in AML | NCT07670130
- ICG415 CAR-T for AML Trial (NCT07668557)
- AML Chemotherapy Trial Comparing LDA, LHAA, LA R NCT07651163
- VA-CAG Two-Week vs. Three-Week for AML - NCT07642453
- Ziftomenib for AML in Japanese Patients – NCT07623616
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], 05505, South Korea
-
BC Cancer Vancouver
Vancouver, British Columbia, V5Z 4E6, Canada
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre hospitalier universitaire de Haut Leveque
Pessac, 33604, France
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Clinico Y Provincial Barcelona
Barcelona, 8036, Spain
-
Cliniques universitaires Saint-Luc
Brussels, 1200, Belgium
-
H Lee Moffitt Cancer Center
Tampa, Florida, 33612-9497, United States
-
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)
Helsinki, 00290, Finland
-
Hopital Saint Louis
Paris, 75010, France
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital Universitario La Fe de Valencia
Valencia, 46026, Spain
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Paoli-Calmettes
Marseille, 13273, France
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medizinische Hochschule Hanover
Hanover, Lower Saxony, 30625, Germany
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
National University Cancer Institute
Singapore, 119228, Singapore
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Princess Margaret Hospital
Toronto, Ontario, M5G2M9, Canada
-
Rambam Medical Center
Haifa, 3109601, Israel
-
Roswell Park Cancer Institute
Buffalo, New York, 14263-0002, United States
-
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Singapore General Hospital
Singapore, 169608, Singapore
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
University of California, Davis - Health Systems
Sacramento, California, 95817, United States
-
University of Chicago Hospital
Chicago, Illinois, 60637, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States